Distinguished in Age-Related Macular Degeneration (ARMD)

Fred K. Chen

Hospital Avenue, 
Nedlands, WA, AU 
Distinguished in Age-Related Macular Degeneration (ARMD)
Hospital Avenue, 
Nedlands, WA, AU 
OverviewLocationsClinical Research

Overview

Fred Chen practices in Nedlands, Australia. Mr. Chen is rated as a Distinguished expert by MediFind in the treatment of Age-Related Macular Degeneration (ARMD). His top areas of expertise are Late-Onset Retinal Degeneration, Retinopathy Pigmentary Mental Retardation, Retinitis Pigmentosa, Stargardt Macular Degeneration, and Vitrectomy.

His clinical research consists of co-authoring 256 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 46 articles and participated in 1 clinical trial in the study of Age-Related Macular Degeneration (ARMD).

Gender
Male

Locations

Hospital Avenue, Nedlands, WA 6009, Australia
Other Locations
2 Verdun Street, Nedlands, WA 6009, Australia
197 Wellington St, Perth, WA 6000, Australia
Wellington Street, Perth, WA 6000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus
A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 09, 2025
Intervention Type: Drug
Study Drug: EXN407
Study Phase: Phase 1/Phase 2
Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine
Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine
Enrollment Status: Completed
Publish Date: August 26, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

256 Total Publications

Phenotypic expansion of retinal abnormalities in folliculin (FLCN) variant-related pathology (Birt-Hogg-Dubé syndrome).
Phenotypic expansion of retinal abnormalities in folliculin (FLCN) variant-related pathology (Birt-Hogg-Dubé syndrome).
Journal: Ophthalmic genetics
Published: November 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chen's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 57 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile